Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center .
The patients, age 60 years or older, received therapy with venetoclax in combination with cobimetinib or idasanutlin. The clinical trial followed...
A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with...
Study results revealed previously unknown interplay between two key enzymes and a novel understanding of how brain cancer tumors form and...
Researchers at The University of Texas MD Anderson Cancer Center will present their latest findings involving drug treatments for blood cancers at the American Society of Hematology’s (ASH) Annual Meeting & Exposition Dec. 8-12 in Atlanta.
“There can be no doubt that we are in an exciting new era of treatment of blood cancers as evidenced by key presentations by MD Anderson researchers at this year’s ASH meeting,” said Patrick...
The University of Texas MD Anderson Cancer Center today welcomes Peter WT Pisters, M.D., as its fifth full-time president in the institution...
In recognition of their contributions to basic, translational, and clinical research, six faculty members from The University of Texas...
Seres Therapeutics, Inc., The University of Texas MD Anderson Cancer Center and the Parker Institute for Cancer Immunotherapy today...
Thousands of patients, family members, volunteers, friends and employees of The University of Texas MD Anderson Cancer Center participated...
The University of Texas MD Anderson Cancer Center Board of Visitors (BOV) welcomed seven new members at its annual meeting today. They include...
A study revealing a connection between circulating tumor cells (CTCs) and relapse in stage IV melanoma patients points to liquid biopsy as...
Deeply entrenched and mature by the time it’s found, pancreatic cancer is one of the hardest to defeat. A Dream Team assembled by Stand...
V. Craig Jordan, Ph.D., professor of Breast Medical Oncology, has been elected to the National Academy of Medicine for his discovery of selective...
A major national effort to expand the reach of cancer immunotherapy to benefit more patients will draw upon the expertise of a team of researchers...
The University of Texas MD Anderson Cancer Center and Belmont Village Senior Living will present a free panel discussion in Austin exploring...
The University of Texas MD Anderson Cancer Center and BridgeBio Pharma today announced the launch of Navire Pharma, a biopharmaceutical company...
The University of Texas MD Anderson Cancer Center and Pfizer Inc. today announced that they have entered into a clinical collaboration...
Diet and exercise may improve treatment outcomes in pediatric cancer patients, according to a study at The University of Texas MD Anderson...
Participating in twice-weekly practice of Tibetan yoga may reduce sleep disturbances and improve sleep quality in breast cancer patients receiving...
Through dedicated teamwork, strategic planning and the support of its internal and external communities, The University of Texas MD Anderson...
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® Seminar to Atlanta for the third time, 8:30-...
The University of Texas MD Anderson Cancer Center’s Michale E. Keeling Center for Comparative Medicine and Research will open its doors to...
Charles Aubrey LeMaistre, M.D.
1924-2017
Charles Aubrey “Mickey” LeMaistre, M.D., beloved physician, father, trusted friend...
The 28th annual A Conversation With a Living Legend® in Dallas, Sept. 14 at the Hilton Anatole, honors architect, artist and engineer Santiago...
The University of Texas MD Anderson Cancer Center again has ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals...
For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy...
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down...
The treatment of osteosarcoma, the most common tumor of bone, is challenging. A study led by The University of Texas MD Anderson Cancer Center...
The University of Texas MD Anderson Cancer Center today announced a new leadership structure designed to enhance teamwork and collaborative...
Just as he has changed the lives of people suffering from a devastating genetic disease, molecular endocrinologist John J. Kopchick, Ph.D....
The University of Texas MD Anderson Cancer Center plans its 19th annual Making Cancer History® seminar in Aspen, free and open to the public...
The University of Texas MD Anderson Cancer Center and Convergent R.N.R. Ltd. (CRnR) today announced a collaboration to further develop new...
Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic...
The University of Texas MD Anderson Cancer Center and Hitachi Healthcare Americas Corporation, have today announced that they have entered...
The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated...
High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients who have...
In a clinical feasibility trial conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast...
All cancer tumors have one thing in common – they must feed themselves to grow and spread, a difficult feat since they are usually in a tumor...
The University of Texas MD Anderson Children’s Cancer Hospital today debuted San Diego Zoo Kids, a new television channel for patients and...
Ronald DePinho, M.D., professor of biology and former president, The University of Texas MD Anderson Cancer Center, is among the recipients...
More than 800 cancer doctors, nurses and scientists from all over the world will gather at The University of Texas MD Anderson Cancer Center...
The University of Texas MD Anderson Cancer Center has announced that Ben Melson will become the institution’s senior vice president and chief...
Guillermina Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected to the prestigious National...
The University of Texas MD Anderson Cancer Center Chair of Immunology Jim Allison, Ph.D., whose pivotal insight to attack cancer by treating...
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® Seminar to Midland, for the second time, 11:...
Oncora Medical, a precision radiation oncology software company, and The University of Texas MD Anderson Cancer Center, today announced a...
An Innovative Research Grant from Stand Up to Cancer will help a University of Texas MD Anderson Cancer Center physician scientist and her...
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger...
A study of racial disparities in health-related quality of life of colorectal cancer patients revealed among several findings, that Hispanics...
Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack...
The 31st annual Polo on the Prairie, a U.S. Polo Association-sanctioned event benefiting cancer research and patient care programs at The...
The University of Texas MD Anderson Cancer Center brings Jim Ray, Ph.D., head of Neuroscience, to Dallas on Thursday, April 20, to lead two...
University of Texas System Chancellor William H. McRaven announced today the appointment of Marshall E. Hicks, M.D., as interim president...
An advanced form of image-guided radiation therapy, known as intensity modulated proton therapy (IMPT), has shown early promise for the treatment...
Ronald A. DePinho M.D., president of The University of Texas MD Anderson Cancer Center, has submitted a letter to Chancellor William H. McRaven...
When Dr. Ron DePinho was named president of The University of Texas MD Anderson Cancer Center by the Board of Regents in 2011, ...
A type of functional brain training known as neurofeedback shows promise in reducing symptoms of chemotherapy-induced nerve damage, or neuropathy...
Cancer prevention specialists from The University of Texas MD Anderson Cancer Center will provide skin cancer screenings free to the public...
It’s what’s missing in the tumor genome, not what’s mutated, that thwarts treatment of metastatic melanoma with immune checkpoint...
Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic...
Discovery of a dual role played by the enzyme phosphoglycerate kinase 1 (PGK1) may indicate a new therapeutic target for glioblastoma, an...
Next-generation cyclin dependent kinase 2/9 (CDK2/9) inhibitors offer a novel way to treat lung cancer with minimal toxic side effects on...
Melanoma patients’ response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies...
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance...
Women with early-stage breast cancer who had an intermediate risk recurrence score (RS) from a 21-gene expression assay had similar outcomes...
Researchers have identified a gatekeeper protein that prevents pancreatic cancer cells from transitioning into a particularly aggressive cell...
Joint Statement from Dr. Joseph M. Herman, Clinical Research Director, Department of Radiation Oncology, The University of Texas MD Anderson...